These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 37751299)

  • 21. SOHO State of the Art Updates and Next Questions | Mechanisms of Resistance to BCL2 Inhibitor Therapy in Chronic Lymphocytic Leukemia and Potential Future Therapeutic Directions.
    Bennett R; Thompson E; Tam C
    Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):795-804. PubMed ID: 35970756
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pairing MCL-1 inhibition with venetoclax improves therapeutic efficiency of BH3-mimetics in AML.
    Hormi M; Birsen R; Belhadj M; Huynh T; Cantero Aguilar L; Grignano E; Haddaoui L; Guillonneau F; Mayeux P; Hunault M; Tamburini J; Kosmider O; Fontenay M; Bouscary D; Chapuis N
    Eur J Haematol; 2020 Nov; 105(5):588-596. PubMed ID: 32659848
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of casein kinase 2 sensitizes mantle cell lymphoma to venetoclax through MCL-1 downregulation.
    Thus YJ; De Rooij MFM; Swier N; Beijersbergen RL; Guikema JEJ; Kersten MJ; Eldering E; Pals ST; Kater AP; Spaargaren M
    Haematologica; 2023 Mar; 108(3):797-810. PubMed ID: 36226498
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL.
    Haselager MV; Kielbassa K; Ter Burg J; Bax DJC; Fernandes SM; Borst J; Tam C; Forconi F; Chiodin G; Brown JR; Dubois J; Kater AP; Eldering E
    Blood; 2020 Dec; 136(25):2918-2926. PubMed ID: 32603412
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia.
    Blombery P; Anderson MA; Gong JN; Thijssen R; Birkinshaw RW; Thompson ER; Teh CE; Nguyen T; Xu Z; Flensburg C; Lew TE; Majewski IJ; Gray DHD; Westerman DA; Tam CS; Seymour JF; Czabotar PE; Huang DCS; Roberts AW
    Cancer Discov; 2019 Mar; 9(3):342-353. PubMed ID: 30514704
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines.
    Merino D; Kelly GL; Lessene G; Wei AH; Roberts AW; Strasser A
    Cancer Cell; 2018 Dec; 34(6):879-891. PubMed ID: 30537511
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of p38 MAPK or immunoproteasome overcomes resistance of chronic lymphocytic leukemia cells to Bcl-2 antagonist venetoclax.
    Avsec D; Škrlj Miklavčič M; Burnik T; Kandušer M; Bizjak M; Podgornik H; Mlinarič-Raščan I
    Cell Death Dis; 2022 Oct; 13(10):860. PubMed ID: 36209148
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclax.
    Marques-Piubelli ML; Schlette EJ; Khoury JD; Furqan F; Vega F; Soto LMS; Wistuba II; Wierda WG; Konopleva M; Ferrajoli A; Strati P
    Leuk Lymphoma; 2021 May; 62(5):1129-1135. PubMed ID: 33327833
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lymphoma cells lacking pro-apoptotic BAX are highly resistant to BH3-mimetics targeting pro-survival MCL-1 but retain sensitivity to conventional DNA-damaging drugs.
    Diepstraten ST; Young S; La Marca JE; Wang Z; Kluck RM; Strasser A; Kelly GL
    Cell Death Differ; 2023 Apr; 30(4):1005-1017. PubMed ID: 36755070
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lisaftoclax in Combination with Alrizomadlin Overcomes Venetoclax Resistance in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Preclinical Studies.
    Zhai Y; Tang Q; Fang DD; Deng J; Zhang K; Wang Q; Yin Y; Fu C; Xue SL; Li N; Zhou F; Yang D
    Clin Cancer Res; 2023 Jan; 29(1):183-196. PubMed ID: 36240005
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma.
    Thus YJ; Eldering E; Kater AP; Spaargaren M
    Leukemia; 2022 Sep; 36(9):2165-2176. PubMed ID: 35725771
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer.
    Goodwin CM; Rossanese OW; Olejniczak ET; Fesik SW
    Cell Death Differ; 2015 Dec; 22(12):2098-106. PubMed ID: 26045046
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting BCL2 with venetoclax is a promising therapeutic strategy for "double-proteinexpression" lymphoma with
    Uchida A; Isobe Y; Asano J; Uemura Y; Hoshikawa M; Takagi M; Miura I
    Haematologica; 2019 Jul; 104(7):1417-1421. PubMed ID: 30523053
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas.
    Boiko S; Proia T; San Martin M; Gregory GP; Wu MM; Aryal N; Hattersley M; Shao W; Saeh JC; Fawell SE; Johnstone RW; Drew L; Cidado J
    Blood; 2021 May; 137(21):2947-2957. PubMed ID: 33259592
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199.
    Bojarczuk K; Sasi BK; Gobessi S; Innocenti I; Pozzato G; Laurenti L; Efremov DG
    Blood; 2016 Jun; 127(25):3192-201. PubMed ID: 27095788
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia.
    Ramsey HE; Fischer MA; Lee T; Gorska AE; Arrate MP; Fuller L; Boyd KL; Strickland SA; Sensintaffar J; Hogdal LJ; Ayers GD; Olejniczak ET; Fesik SW; Savona MR
    Cancer Discov; 2018 Dec; 8(12):1566-1581. PubMed ID: 30185627
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PP2A modulation overcomes multidrug resistance in chronic lymphocytic leukemia via mPTP-dependent apoptosis.
    Jayappa KD; Tran B; Gordon VL; Morris C; Saha S; Farrington CC; O'Connor CM; Zawacki KP; Isaac KM; Kester M; Bender TP; Williams ME; Portell CA; Weber MJ; Narla G
    J Clin Invest; 2023 Jul; 133(13):. PubMed ID: 37166997
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic events associated with venetoclax resistance in CLL identified by whole-exome sequencing of patient samples.
    Khalsa JK; Cha J; Utro F; Naeem A; Murali I; Kuang Y; Vasquez K; Li L; Tyekucheva S; Fernandes SM; Veronese L; Guieze R; Sasi BK; Wang Z; Machado JH; Bai H; Alasfour M; Rhrissorrakrai K; Levovitz C; Danysh BP; Slowik K; Jacobs RA; Davids MS; Paweletz CP; Leshchiner I; Parida L; Getz G; Brown JR
    Blood; 2023 Aug; 142(5):421-433. PubMed ID: 37146250
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synergistic activity of combined inhibition of anti-apoptotic molecules in B-cell precursor ALL.
    Seyfried F; Stirnweiß FU; Niedermayer A; Enzenmüller S; Hörl RL; Münch V; Köhrer S; Debatin KM; Meyer LH
    Leukemia; 2022 Apr; 36(4):901-912. PubMed ID: 35031695
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blockage of BCL-XL overcomes venetoclax resistance across BCL2+ lymphoid malignancies irrespective of BIM status.
    Dolnikova A; Kazantsev D; Klanova M; Pokorna E; Sovilj D; Kelemen CD; Tuskova L; Hoferkova E; Mraz M; Helman K; Curik N; Machova Polakova K; Andera L; Trneny M; Klener P
    Blood Adv; 2024 Jul; 8(13):3532-3543. PubMed ID: 38713893
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.